Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13207918 | 0.90 | LMNA (0.45) | SNCAPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL13207912 | 0.90 | LMNA (0.45) | SNCAPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL10110953 | 0.89 | ALDH1A1 (0.44) | SNCAPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL4908045 | 0.88 | LMNA (0.53) | PTGS2PTGS1ALDH1A1LMNACA1 | |
| SCHEMBL7510471 | 0.86 | CA12 (0.47) | SNCAPTGS2ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL29111205 | 0.86 | RAPGEF4 (0.44) | SNCAPTGS2PTGS1ALDH1A1LMNA | |
| SCHEMBL778956 | 0.86 | PTGS2 (0.50) | PTGS2PTGS1FFAR4 | |
| SCHEMBL3151103 | 0.86 | ALDH1A1 (0.48) | SNCAPTGS2KDM4EALDH1A1LMNA | |
| SCHEMBL11324926 | 0.85 | ALDH1A1 (0.45) | SNCAKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL7624637 | 0.83 | PTGS2 (0.48) | PTGS2PTGS1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6403801-B1 | MIXING IN LIQUID MEDIUM STRONG BASE, ARYL HALIDE OR ARYL PSEUDOHALIDE, ARYLBORONIC ACID, NICKEL, PALLADIUM OR PLATINUM COMPOUND, N-HETEROCYCLIC CARBENE SELECTED FROM IMIDAZOLINE-2-YLIDENE, BIS(IMIDAZOLINE-2-YLIDENE) OR SALTS | UNIVERSITY OF NEW ORLEANS RESEARCH & TECHNOLOGY FOUNDATION | 2002-06-11 | — | — | US | claimed |
| WO-2001066248-A2 | C-C AND C-N COUPLING CATALYST COMPRISING TRANSITION METAL AND CARBENE | UNIVERSITY OF NEW ORLEANS RESEARCH AND TECHNOLOGY FOUNDATION (US) | 2001-09-13 | — | — | WO | claimed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
| US-6235938-B1 | ARYLATION IN THE PRESENCE OF A BASE AND TRANSITION METAL CATALYSTS TO FORM N-ARYLAMINE AND GROUP 8 METAL | YALE UNIVERSITY | 2001-05-22 | — | — | US | disclosed |
| US-6072073-A | REACTING COMPOUND HAVING CARBONYL GROUP WITH ARYLATING OR VINYLATING COMPOUND IN PRESENCE OF BASE AND TRANSITION METAL CATALYST | YALE UNIVERSITY (US) | 2000-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | SNCA 4582/4885PTGS2 3184/4885PTGS1 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.